Seda Kanmaz1, Erdem Simsek2, Hepsen Mine Serin2, Sanem Yilmaz2, Gul Aktan2, Hasan Tekgul2, Sarenur Gokben2. 1. Department of Pediatrics, Division of Child Neurology, Ege University Medical Faculty, 35100, Bornova, Izmir, Turkey. drsedakanmaz@gmail.com. 2. Department of Pediatrics, Division of Child Neurology, Ege University Medical Faculty, 35100, Bornova, Izmir, Turkey.
Abstract
PURPOSE: Sulthiame (STM) has been recommended as an effective antiepileptic drug (AED) in children with epileptic encephalopathy with status epilepticus in sleep (ESES). The aim of this study is to evaluate the efficacy of STM add-on treatment in children with pattern of ESES with respect to the etiologic subgroup. METHODS: Twenty-nine children with ESES pattern with three different etiologic subgroups (epileptic syndromes: 14, structural/infectious: 9, unknown: 6) who were given STM as add-on treatment were included into the study. The efficacy of STM was evaluated in terms of seizure control, electroencephalography (EEG) findings, need of the new AEDs after add-on STM, and behavioral and cognitive improvement. RESULTS: The range of the follow-up duration after add-on STM treatment was between 5 and 51 months. At the end of 1 year of STM treatment, the most successful electrophysiologic improvement was identified in the well-defined epileptic syndrome group; epileptic syndrome, 71.4% (10/14); structural/infectious, 33.3% (3/9); and unknown, 0% (0/6). Patients who had complete response or persistent ESES pattern at the 3rd month were still in the same condition at the 6th and 12th months. However, the ESES pattern reappeared in 35.2% of the patients who had partial electrophysiological improvement at the 3rd month. In the epilepsy syndrome group, eight out of ten patients who had either complete or partial EEG response after 1 year of STM treatment displayed behavioral and cognitive improvement. CONCLUSION: Sulthiame might be a valid add-on treatment of ESES especially in children with epilepsy syndromes.
PURPOSE:Sulthiame (STM) has been recommended as an effective antiepileptic drug (AED) in children with epileptic encephalopathy with status epilepticus in sleep (ESES). The aim of this study is to evaluate the efficacy of STM add-on treatment in children with pattern of ESES with respect to the etiologic subgroup. METHODS: Twenty-nine children with ESES pattern with three different etiologic subgroups (epileptic syndromes: 14, structural/infectious: 9, unknown: 6) who were given STM as add-on treatment were included into the study. The efficacy of STM was evaluated in terms of seizure control, electroencephalography (EEG) findings, need of the new AEDs after add-on STM, and behavioral and cognitive improvement. RESULTS: The range of the follow-up duration after add-on STM treatment was between 5 and 51 months. At the end of 1 year of STM treatment, the most successful electrophysiologic improvement was identified in the well-defined epileptic syndrome group; epileptic syndrome, 71.4% (10/14); structural/infectious, 33.3% (3/9); and unknown, 0% (0/6). Patients who had complete response or persistent ESES pattern at the 3rd month were still in the same condition at the 6th and 12th months. However, the ESES pattern reappeared in 35.2% of the patients who had partial electrophysiological improvement at the 3rd month. In the epilepsy syndrome group, eight out of ten patients who had either complete or partial EEG response after 1 year of STM treatment displayed behavioral and cognitive improvement. CONCLUSION:Sulthiame might be a valid add-on treatment of ESES especially in children with epilepsy syndromes.
Authors: Mohammed Ghiath Shamdeen; Wolfram Jost; Martina Frohnhöfer; Ludwig Gortner; Sascha Meyer Journal: Pediatr Int Date: 2012-09-11 Impact factor: 1.524
Authors: Moritz Tacke; Ingo Borggraefe; Lucia Gerstl; Florian Heinen; Katharina Vill; Michaela Bonfert; Thomas Bast; Bernd Axel Neubauer; Friedrich Baumeister; Martina Baethmann; Karl Bentele; Christian Blank; Harald M Blank; Harald Bode; Friedrich Bosch; Ulrich Brandl; Knut Brockmann; Peter Dahlem; Jan-Peter Ernst; Evemarie Feldmann; Andreas Fiedler; Michael Gerigk; Soeren Heß; Christiane Hikel; Hans-Georg Hoffmann; Matthias Kieslich; Joerg Klepper; Gerhard Kluger; Hartmut Koch; Walter Koch; Rudolf Korinthenberg; Ilona Krois; Hermann Kühne; Gerhard Kurlemann; Michaela Mandl; Ulrike Mause; Peter Navratil; Joachim Opp; Johann Penzien; Viola Prietsch; Axel Quattländer; Dietz Rating; Ulrike Schara; Mohammed G Shamdeen; Andreas Sprinz; Hildegard Wendker-Magrabi; Ulrich Stephani; Hiltrud Muhle; Hans-Michael Straßburg; Bärbel Töpke; Regina Trollmann; Elisabeth Tuschen-Hofstätter; Stephan Waltz; Gabriele Weber; Frank U Wien; Markus Wolff; Tilman Polster; Hedwig Freitag; Ötzcam Sönmez; Klaus Reinhardt; Marion Traus; Zeecam Hoovey Journal: Seizure Date: 2018-02-03 Impact factor: 3.184